2015ANNUAL REPORT

TABLE OF CONTENTS

1

3

4

5

6

7

9

12

13

14

15

16

17

18

19

“USVP looks for compelling science and top management talent. I have been

impressed with the portfolio of medical device and therapeutic companies that

BioGenerator is building.”

-John Root, MDGeneral Partner, USVP

LETTER FROM THE PRESIDENTOUR APPROACH2015 INVESTMENTSNEW COMPANIES IN 20152015 CAPITAL RAISESOUR FULL PORTFOLIO COMPANY HIGHLIGHTSCOMPANY UPDATESBIOGENERATOR LABSLABS CLIENTSCEO HIGHLIGHTSTEAMENTREPRENEURS IN RESIDENCEINVESTMENT ADVISORY COMMITTEEABOUT BIOGENERATOR

LETTER FROM THE PRESIDENT

1

BioGenerator strives to balance a complex set of factors necessary to achieve our strategic objectives: building strong companies; investing in a diverse range of life science sectors; creating companies with a range of business models from high reward technologies that generate strong returns to investors, to others that achieve revenue more quickly or create sustainable jobs; expanding the St. Louis talent pool; educating first-time entrepreneurs; and assisting regional partners. To achieve these objectives over the last year, BioGenerator’s team held over 400 meetings with entrepreneurs, engaged with 175 venture capital, strategic, and private equity firms, provided capital to over 20 pre-investment projects, evaluated over 300 investment opportunities, completed 32 investment transactions, held 30 portfolio company board seats, and consistently applied an approach embodied by commitment, rigor, and problem-solving.

2015 was characterized by continued maturation of BioGenerator’s investment portfolio, highlighted by several noteworthy financings. We deployed over $2.8M as investments into portfolio companies. We seek to align invested capital with quality of companies, reserving larger amounts of capital for our highest quality and most mature companies and deploying smaller amounts of risk capital into early-stage companies. The scope of 2015 investments ranged from $25K in initial funding of concept stage companies targeting novel approaches to agriculture and therapeutics to, at the other end of the spectrum, post-seed funding of companies that have received multiple investments from us over time. In addition, at the earliest stage of company formation, we provided pre-investment capital, advice, facilities, and services to a number of emerging technologies and newly-formed companies.

BioGenerator added 8 new companies to our portfolio in 2015. BioGenerator is often the first investor in new companies and frequently serves as the lead investor in pre-institutional financings and assists in value creation through active board of directors

engagement post-investment. Three of our new investments were in the ag sector, including an Argentinian firm, S4 Agtech, that chose St. Louis as its US base of operations, reflecting increased quality of deal flow in the ag sector over the past two years, spurred by increasing local, national, and even global recognition that the St. Louis region is an attractive location for ag-based startups. Deal flow in the healthcare IT sector continues to emerge; St. Louis has an opportunity to combine talent from its growing IT sector with resident healthcare expertise. Diversification of deal flow, along with intentional efforts on the part of our staff, are driving greater balance across life sciences sectors.

Last year we highlighted challenges faced by our portfolio of maturing companies. In Q3 2013, we launched our Post-Seed fund in recognition of the capital gap between seed funding and venture rounds led by major institutional investors. This funding mechanism enabled us to help catalyze or assemble syndicated rounds, facilitating achievement of key milestones designed to secure next-level financing. In 2015, we continued to allocate a substantial portion of our annual investment budget to this purpose, committing over $2M into syndicated rounds for our later stage portfolio. BioGenerator’s commitment to one or more rounds of financing beyond the seed stage, with an emphasis on syndicated rounds for our strongest companies, is paying dividends. Four of our later-stage companies closed on Series A or B rounds in 2016 that ranged from $7.3M to $45M in committed capital. Several of these large financings were structured to fund companies to exit, demonstrating that institutional financiers perceived these as high value opportunities.

Overall our portfolio has made great strides in raising capital over the past few years. From 2013 – 2015, BioGenerator invested about $3M - $3.5M per year across the portfolio. In 2013, BioGenerator capital was augmented with an additional $21M, syndicated with us or as follow-on investments. In 2014, the

2

Eric GulvePresident, BioGenerator

leverage from additional sources reached approximately $45M, with well over half of the 2014 financing coming from outside the St. Louis region. I’m excited to report that in 2015, we set a new internal mark - total capital sourced across the portfolio was roughly $145M, with over 80% from outside St. Louis. Portfolio company financing successes were catalyzed in part by BioGenerator’s business development activities at our Boston office, through which 175 investment firms were engaged in 2015. The BioGenerator Labs, which we expanded in 2013, are a critical enabler of our investment strategy and our overall regional support for bioscience entrepreneurial endeavors. A key premise is that the space, which includes state-of-the-art specialized equipment, is shared. We have jettisoned the model that defines startup companies by how much space and equipment they “own.” In contrast, the Labs model incorporates high density occupancy, realizing substantial economic efficiencies in a setting that enables cooperation and collaboration, and focuses capital resources on technology de-risking and value creation. In 2015, occupancy grew to over 50 startups. The Labs are home to dozens of highly experienced former industry scientists who are now working in startups, co-mingling with university faculty, students, post-docs, and entrepreneurs. With minimal incremental cost to add users, the Labs enable us to support exciting, high risk/high impact, early-stage ideas emanating from the community: from first-time entrepreneurs, our research institutions, and industry veterans.

In 2015, BioGenerator received an i6 Challenge grant from the US Department of Commerce to support early stage technology commercialization. The program leverages expertise of our staff and professional networks to evaluate business and technical viability of university-based and other pre-commercial innovations via non-dilutive funding. BioGenerator will create a portfolio of pre-investment opportunities with the i6 Challenge grant.

This report would not be complete without our thanks to the many organizations and individuals that support BioGenerator and our parent organization, BioSTL. BioGenerator could not achieve its objectives without the strong support of BioSTL’s Board and the generous funding commitments of our stakeholders. The vision and long-term support from Dr. William Danforth, John McDonnell, and Donn Rubin have been essential to our success, as has the support of the BioSTL Board over the past four and a half years. Major 2015 funders of BioSTL and, by extension, of BioGenerator include Washington University, BJC HealthCare, St. Louis Life Sciences Project, Monsanto, Boeing, Ascension Health, Crawford-Taylor Foundation, Mallinckrodt Pharmaceuticals, MilliporeSigma, Blackstone Charitable Foundation, and the JPMorgan Chase Foundation. We have also received funding for specific activities from public sector entities: Missouri Technology Corporation, the Helix Fund of St. Louis County, the US Economic Development Administration, and the US Small Business Administration. In addition, we are indebted to BioGenerator’s seed stage Investment Advisory Committee whose members generously donate their time and expertise. We are eternally grateful to each of these entities and individuals for their support and commitment.

As President of BioGenerator, I’m grateful for the opportunity to lead our team and am excited about opportunities to improve human health, food production, and the environment while helping to transform the St. Louis economy in 2016 and beyond.

OUR APPROACH

INVESTMENT ACTIVITY

ALIGNMENT OF CAPITAL AND QUALITY

3

We position our portfolio companies to raise syndicated and follow-on investments and to navigate the unique challenges of company development. With the goal of removing barriers to entrepreneurial success, we collaborate with our portfolio companies in three primary ways:

Access to capital by making investments across multiple stages and developing strategic relationships with qualified investors

Strategic advisory services to innovators and entrepreneurs, focused on company building and identifying strong talent

Collaborative lab space and state-of-the-art equipment to create capital efficiency for portfolio companies

The BioGenerator investment philosophy emphasizes making the largest investments in companies who prove, over time and based on accomplishment of milestones, that they are the most likely to achieve success and return capital to investors.

2015 INVESTMENTS

PRE-SEED FUND SEED FUND POST-SEED FUND

BIOGENERATOR

INVESTED IN 26

COMPANIES IN 2015

4

BACTERIOSCAN*

BENSON HILLCARDIALEN

CONFLUENCEEUCLISES*

GENERICO*

NEUROLUTIONS*

VASCULOX*

ACCURONIX*

ARCH INNOTEK*

COFACTOR GENOMICSELIRA*

EPHARMIXINOVOTECKATALYST

MEDSOCKETS4

SANUSEOSYNERZ

YOURBEVCO

ANTEGRINAPSE

ARVEGENIXEUCLISES*

KOGENT

PRE-INVESTMENTPROJECTS (1)

ASTRISKALOCYTE

FRAGRANCE COCOURIER

CARDIAFORMUNLEASH*

NIROGAWU SENSOR CO

PRO-ARCLAB TOOLS CO

CONCEPT FUND

NITROGENICSACCURONIX*

UNLEASH*

(1) Representative list of pre-investment projects; includes pre-company and other activities such as i6 Proof of Concept Center*Companies received multiple investments in 2015

EXAMPLE 2015 NEW DEALS

5

Investment from BioGenerator helps Cofactor Genomics grow in Cortex

Cofactor Genomics uses RNA to diagnose disease. The company, backed by Y Combinator, works with the largest life sciences and pharmaceutical companies in the world and is developing unique technologies and software that use RNA to inform disease status.

“We believe that Cofactor Genomics is poised to take great strides,” said Jarret Glasscock, founder and CEO of Cofactor. “As a partner for several years, we were pleased to welcome BioGenerator as an investor.”

BioGenerator led a $1.5M round for Washington University startup Epharmix

Epharmix is a health IT company offering interventions that use automated phone calls or text messages to manage patients’ conditions while collecting disease-specific data. Each intervention is designed by physicians & clinically proven at top institutions.

“Epharmix’s technology will increase efficiency and quality for patients and physicians, and our team is looking forward to growing with the help of this investment from BioGenerator,” said Blake Marggraff, founder and CEO of Epharmix.

BioGenerator investment helps S4 expand Argentina operations to St. Louis

S4 uses satellite images of farm fields around the world and data analytics to predict crop yields, allowing users of the product to make more informed decisions and better allocate their resources. S4 was accepted in to The Yield Lab in 2015.

“BioGenerator has been very important in our decision to locate our North American headquarters to St. Louis,” said Tomás Peña, cofounder and CFO of S4. “They have been very instrumental in helping us put our financing round together and will be a valuable partner in the years to come.”

2015 CAPITAL RAISES

6

2013 2014 2015

“BioGenerator is a significant value-add investor. The professionalism they brought to due diligence and the process allowed us to

move very quickly.”

– Sach ChitnisManaging Partner, Jump Capital

$50M

$100M

$150M

BioGenerator portfolio companies have continued to raise increasing

amounts each year.

BioGenerator companies raised $145M in 2015, continuing growth seen from 2013-2014. Example financings for BioGenerator portfolio companies in 2015 include:

MediBeacon - In 2015, MediBeacon closed $22.4M in staged financing from Pansend/HC2 Holdings. In partnership with Washington University, MediBeacon also previously received a Gates Foundation grant.

Benson Hill - In 2015, Benson Hill completed a Series A round of $7.3M with participation from Middleland, Mercury Fund, Prelude Ventures, and Cultivation Capital. The company has also secured strategic partnerships.

Vasculox - In 2015, Vasculox completed a Series A round of up to $45M. The financing was led by RiverVest, Novo, and SR One. The company has also been awarded significant SBIR/STTR grants.

Galera - In 2015, Galera raised a $37M Series B, with participation from Novo, NEA, Novartis, and Correlation. Galera has raised over $63M and is in clinical trials for cancer and other indications.

“2015 was a landmark year for BioGenerator portfolio

company funding. Our deals are starting to garner attention from an increasing number of

top-tier venture funds.”

– Edward HamatiDirector, BioGenerator

Boston Office

Am

oun

t Rai

sed

(Clo

sed

& C

om

mitt

ed

)

FULL PORTFOLIO

CONCEPT FUNDNITROGENICS

AGRICULTURE

PRE-SEED FUND

7

UNLEASHTHERAPEUTIC

52 active

BioGenerator companies

ACCURONIXTHERAPEUTICS

ARCH INNOTEKNUTRITION

COFACTOR GENOMICS CRO & DIAGNOSTICS

DAYA CNSTHERAPEUTICS

EDIS HEALTH IT

ELIRA THERAPEUTICSMED DEVICE

EPHARMIXHEALTH IT

EPIGENETXTHERAPEUTICS

IMMUNOPHOTONICSTHERAPEUTICS

INOVOTEC AGRICULTURE

KATALYSTMED DEVICE

MEDSOCKETHEALTH IT

MOBIUS ABXTHERAPEUTICS

NANOPOREDIAGNOSTICS

PMDIDIAGNOSTICS

SANUSEOHEALTH IT

SYNERZMED DEVICE

TANSNATHERAPEUTICS

TRAXXSSONDIAGNOSTIC

X-TEND ENERGYCLEAN TECH

YOURBEVCOCPG

S4AGRICULTURE

ARRAY BRIDGERESEARCH TOOLS

“The deal flow coming from BioGenerator has

matured significantly and I’ve been impressed by the companies being

developed in St. Louis.

-George AridaManaging Director,Venture Investors

SEED FUND

POST- SEED FUND

GRADUATES & EXITS

8

$325Madditional funding attracted by BioGenerator companies

ANTEGRINTHERAPEUTICS

APSEAGRICULTURE

ARVEGENIXAGRICULTURE

GRAEMATTERHEALTH IT

KOGENTMED DEVICE

ADARZARESEARCH TOOLS

BENSON HILLAGRICULTURE

CARDIALENMED DEVICE

CONFLUENCE LIFE SCIENCESTHERAPEUTICS

EUCLISESTHERAPEUTICS

GENERICOTHERAPEUTICS

NEUROLUTIONSMED DEVICE

APT THERAPEUTICSTHERAPEUTICS

KYPHADIAGNOSTIC

PULSE THERAPEUTICSMED DEVICE

BACTERIOSCANMED DEVICE

AKERMINCLEAN TECH

APERTUSCRO

CONFLUENCE DISCOVERYCRO

ELECTROCHAEACLEAN TECH

GALERATHERAPEUTICS

IONIC TRANSPORTCRO

MEDIBEACONMED DEVICE

MOBIUSTHERAPEUTICS

VASCULOXTHERAPEUTICS

SARMONTCRO

PIXELEXXRESEARCH TOOL

$13.1 Mcumulative

BioGenerator investment

COMPANY HIGHLIGHTS

9

BacterioScan is a commercial stage medical device company with technology to rapidly detect bacterial growth. BacterioScan’s first product detects and measures bacterial growth from clinical urine samples quickly, precisely, and with minimal labor. Earlier detection supports faster, more appropriate determination of treatment and better patient care, while reducing costs incurred today with both false positive and false negative results.

BioGenerator invested in BacterioScan’s Series A financing and assisted the company in raising follow-on capital. BioGenerator has made three investments in BacterioScan, providing critical capital as the company has moved from proof of concept stage to its initial product launch in 2015.

“BacterioScan’s technology is a fast and accurate solution for bacterial detection. It should reduce healthcare spend and unnecessary antibiotic usage.”

-Dan Broderick

Vasculox is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company’s functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. The company was co-founded by William Frazier, professor at Washington University.

As the first investor in Vasculox, BioGenerator provided capital and support to expand the company’s team, develop a panel of lead candidates, demonstrate pharmacology in oncology models, and raise follow-on capital. BioGenerator has made three investments in Vasculox, and in 2015, the company closed a significant Series A financing.

“CD47 is an opportune target in immuno-oncology. Vasculox leverages outstanding research and pharma expertise to provide unique insight into the target.”

-Charlie Bolten

10

Benson Hill Biosystems is an agricultural company seeking to increase crop productivity, principally by improving the efficiency of photosynthesis. Benson Hill benefits from leading academic founders at Donald Danforth Plant Science Center, management comprised of experienced agbiotech executives, and strategic partnerships with agricultural companies for multiple crops.

Benson Hill’s first financing and move to St. Louis were led by BioGenerator, which subsequently invested two additional times to fuel the company’s growth. Since BioGenerator’s initial financing, Benson Hill has established strategic partnerships, built a robust R&D team and research facility, validated its technology with field trials, and raised significant capital.

Cardialen is revolutionizing atrial fibrillation (AF) treatment through a low energy, implantable device. The therapy has the potential to detect and terminate arrhythmias, slow disease progression, and greatly reduce AF’s substantial financial burden for patients and payers. Cardialen was founded by Igor Efimov and is based on technology invented at Washington University.

BioGenerator was the lead investor in Cardialen’s founding round of financing, providing capital to demonstrate preclinical proof of concept, develop prototypes, initiate clinical testing, add management talent, and raise follow-on capital. BioGenerator has made four investments in Cardialen, enabling generation of early clinical data in 2015.

“Cardialen is developing potentially game-changing technology for treatment of AF, an area of unmet clinical need with a significant market opportunity.”

-Eric Gulve

“Increased yield adds great economic and societal value. Benson Hill enhances fundamental pathways that convert the sun’s energy to salable products.”

-Dan Broderick

COMPANY HIGHLIGHTS

11

MediBeacon is a clinical stage company developing technology to measure kidney function in real-time. Today, standard methods provide indirect estimates reflective of the status of renal function several days prior. MediBeacon’s Optical Renal Function Monitor measures, rather than estimates, kidney function and does so in real-time.

Having assisted MediBeacon in securing key technology assets, BioGenerator led the company’s first financing. As MediBeacon progressed, BioGenerator has invested three times to help catalyze the company’s early funding rounds. MediBeacon made significant progress toward a commercial product in 2015 with additional clinical data and an institutional financing.

“Through strategic acquisition of a clinical ready asset, MediBeacon has moved quickly toward an important product with a large market opportunity.”

-Charlie Bolten

Adarza BioSystems produces next generation, label-free, multiplex protein assays. The company’s platform has high sensitivity, broad dynamic range, and significant workflow advantages. The versatility of the Adarza platform means that it can serve as a central tool for evaluating a broad range of important biological problems.

BioGenerator recruited Adarza to St. Louis, was the company’s first regional investor in 2013, and subsequently led a Seed financing. BioGenerator has invested two times in Adarza as the company progressed. Adarza made significant progress toward a commercial product in 2015, established a St. Louis manufacturing facility, and expanded its strategic partnerships.

“Unraveling complex biology requires measuring many markers simultaneously. Adarza offers the unique ability to do this at the protein level.”

-Edward Hamati

COMPANY UPDATES

12

NEUROLUTIONSNeurolutions is developing devices based on Brain Computer Interface technology, that target functional restoration in neurological injury patients. Founders include Washington University professors Eric Leuthardt and Dan Moran. In 2015, Neurolutions closed financing with participation from Ascension Health Ventures and BioGenerator (founding investors), along with Prolog, enabling prototype refinement and completion of initial clinical studies with its lead product, the IpsiHand, in chronic stroke patients.

ARVEGENIXArvegenix is commercializing Field Pennycress as an oilseed crop that will produce high quality oil for industrial and renewable fuels, along with meal for livestock feed. Pennycress is a winter crop grown between corn and soybeans when land is idle. BioGenerator was a founding investor of Arvegenix in 2014, after incubating the idea pre-company. Arvegenix closed a Series A financing in 2015 with participation from Monsanto Growth Ventures, Prelude Ventures, Cultivation Capital, Prolog, MTC, and BioGenerator.

APSEApse produces RNAi products for use in agriculture and other large scale applications. The company’s novel manufacturing method enables production of RNAi-based products at a fraction of the cost compared to conventional methods. BioGenerator was a founding investor in Apse. In 2015, under the leadership of new CEO John Kilmer, former President of Monsanto China, Apse made significant advancements in proving its manufacturing method at scale and applying the process to its RNAi product candidates.

GENERICOGeneriCo has assembled a portfolio of niche generic pharmaceuticals, particularly those requiring embedded drug delivery technology. BioGenerator led the company’s first financing in 2013 when the company was created by former BioGenerator Entrepreneur in Residence and current GeneriCo CEO Tom Brya. In 2015, the company established critical strategic partnerships around its lead products and closed a $1.5M Series A financing with participation from Kinsale Partners, MTC, and BioGenerator.

EUCLISESEuclises is developing best-in-class Cox-2 inhibitors for cancer. BioGenerator was the first investor backing renowned chemist John Talley at the BioGenerator Labs, and later led the first external financing of the renamed Euclises Pharmaceuticals. Former BioGenerator Entrepreneur in Residence Rajesh Devraj refined the company’s strategy, in-licensed key IP, and raised a Series A offering before the recruitment of current CEO Bobby Sandage. In 2015, the company took important steps toward testing in patients.

BIOGENERATOR LABSThe BioGenerator Labs provide access to collaborative lab and office space and state-of-the-art equipment for portfolio and pre-investment technologies. The BioGenerator Labs are a critical asset to increase efficiency of early stage technology development by:

Increasing capital efficiency for client companies via access to substantial amounts of scientific equipment Concentrating world class talent in a single facility adjacent to Washington University’s campus Fostering an innovative and collaborative environment

The BioGenerator Labs is an 18,000 square-foot facility equipped for bioscience research, located in St. Louis’ midtown Cortex Innovation Community. Access to facilities are provided to promising companies and pre-investment technologies, reducing startup costs for client companies while focusing investment capital on technology de-risking and value creation. The Labs have more than 50 client companies and many more pre-company projects.

LABS CLIENTS

14

ACCURONIX*ADARZA*

ANTEGRIN*APSE*

ARCH INNOTEK*ARRAY BRIDGE*

ASTRIS THERAPEUTICSAVEXI PHARMA

CELLATRIXCOMMON PLACE HOLDINGSCONFLUENCE DISCOVERY*

CONFLUENCE LIFE SCIENCES*CONTREMETS

DIRECTED DRUG DELIVERYEDIS*

EPIGENETX*EUCLISES* FIMBRION

GATEWAY BIOTECHNOLOGYGENEOSCOPY

GENERICO*HEALTH ADLYTICS

HEMADVANCEIMMUNOPHOTONICS*

KALOCYTEKYPHA*

MAGBIOSENSEMATATU

MEDIBEACON*MEDICAL GUIDANCE SYSTEMS

NANOPORE*NAWGENNIROGA

OPENCELL TECHNOLOGIESPRECISION VIROLOGICSPROARC DIAGNOSTICSPULSE THERAPEUTICS*

RESPONDOMESARMONT*

SARTA PHARMACEUTICALSSCI-ENGI-MEDCO

SERIONSEVEN SIGHTS*

SPECTRUM PERCEPTIONSYNERZ*TANSNA*

TARGETED THERAPEUTICSTETRA IMAGING

UNLEASH*VIBA THERAPEUTICS

VASCULOX*YOURBEVCO*

* BIOGENERATOR INVESTMENT PORTFOLIO

CEO HIGHLIGHTS

15

JERRY STEINERARVEGENIX

SEAN MORRIS PULSE THERAPEUTICS

PAULA SKJEFTECARDIALEN

BOBBY SANDAGE EUCLISES

Sean has over 20 years of experience in the medical device sector. Prior to joining Pulse, Sean was the Founder and CEO of Veniti, driving the company through European approval and launch of the very successful Vici Venous Stent™. As CEO for Veniti, Sean successfully raised in excess of $30M to fund operations. Prior

to Veniti, he held various executive positions with AngioDynamics, his last post being the Sr. Vice President and General Manager of the Peripheral Vascular Division where he had P&L responsibility of an enterprise exceeding $150M in annual sales. As CEO of Pulse, Sean has advanced the company’s clinical and regulatory strategy and secured critical financing that will enable the company to build considerable value.

Bobby has over 30 years of experience and a successful track record of developing new therapeutics. He most recently served as CEO of Coronado Biosciences and was previously VP of Covidien’s oncology R&D program. For 19 years, Bobby was the CSO and EVP of R&D at Indevus Pharmaceuticals.

He has also held senior positions at DuPont/Merck, DuPont/American Critical Care, Merrell Dow, and Dow Pharmaceuticals. Bobby is an advisor to various investment funds and startups, including board roles. As CEO of Euclises, Bobby has raised capital and advanced the company to IND-enabling studies.

Paula brings over 30 years of healthcare experience to Cardialen, a clinical stage medical device company. Her experience includes roles as VP of Marketing in Cardiac Rhythm Management and VP of Consumer Business with Medtronic, Inc., and as President and CEO of Waterford Consulting, a company focused on driving

strategic growth in medical technology through innovation, disruptive market approaches, and creative commercialization. As CEO, Paula has guided Cardialen through multiple financings, expansion of the IP portfolio, completion of preclinical studies, and initial human therapy evaluation.

Jerry has 33 years of agricultural and life science experience. Prior to Arvegenix, Jerry spent most of his career with Monsanto in a variety of roles including crop marketing/sales, animal ag, strategy, global commercialization, public policy, public acceptance for biotechnology, and governmental and industry affairs.

He was Executive VP reporting to the Monsanto CEO and a member of the Executive Team. In 2000-01 he worked for Celera Genomics as Executive VP of Genomic Services. As CEO of Arvegenix, Jerry has built a strong leadership team and raised Series A financing.

TEAM

ERIC GULVE, PH.D.PRESIDENT

DAN BRODERICKVICE PRESIDENT

CHARLIE BOLTENVICE PRESIDENT

EDWARD HAMATIDIRECTOR

ERIC MILLER, PH.D.SENIOR INVESTMENT ANALYST

CRYSTAL WINKELER, PH.D.SENIOR INVESTMENT ANALYST

CHARLENE BUCKLEYPROGRAM COORDINATOR

KAMYLA TOMISEREXECUTIVE ASSISTANT

ENTREPRENEURS IN RESIDENCE

17

RANDY LANGSTONMEDICAL DEVICES

ALAN MACINNESCPG, THERAPEUTICS

SCOTT GLOVERDIAGNOSTICS

DAVID CHRISTENSONHEALTHCARE IT

DAVID SMOLLER, PH.D.RESEARCH TOOLS

PAUL OLIVO, M.D., PH.D.DIAGNOSTICS, THERAPEUTICS

JIM MCCARTER, M.D., PH.D.NUTRITION, HEALTH IT, AGTECH

BioGenerator Entrepreneurs in Residence (EIRs) are experienced professionals with diverse expertise including investing, fundraising, management, operations, and industry R&D. EIRs focus on supporting BioGenerator portfolio companies and creating new ventures.

INVESTMENT ADVISORY COMMITTEENATHAN LAKEY

CHAIRMAN CEO, ORION GENOMICS

BRIAN CLEVINGER, PH.D.PROLOG VENTURES

PETER FINLEYPROSPER ACCELERATOR

MARY JO GORMAN, M.D.FOUNDER, ADVANCED ICU CARE

MICHAEL KINCH, PH.D.WASHINGTON UNIV. ST. LOUIS

STEVE HANLEYCEO, MEDIBEACON

JOHN MCKEARN, PH.D.RIVERVEST VENTURE PARTNERS

RAUL PEREZ, M.D.OAKWOOD MEDICAL VENTURES

RICK RYAN, PH.D.CULTIVATION CAPITAL

WALTER SMITHCEO, CONFLUENCE LIFE SCIENCES

DAVID SMOLLER, PH.D.CULTIVATION CAPITAL

18

“BioGenerator’s commitment to supporting Benson Hill in multiple ways beyond their share of invested capital is part of the reason we are

excited to call St. Louis home.”

–Matthew B. CrispCEO, Benson Hill BioSystems

“BioGenerator was the lead investor for our seed financing and has remained actively engaged in Cardialen. Their respect and connections in the industry have been

invaluable to us. And we knew we could count on them for follow-on funding as we

progressed and grew the company. They have been a true partner.”

– Paula SkjefteCEO, Cardialen

BioGenerator’s total investment of

$13.1M has been leveraged

25 to 1

ABOUT BIOGENERATOR

“BioGenerator has been instrumental in opening up the commercialization of creative

life sciences research being performed in the St. Louis region. That sounds easy, but it

is a very difficult, long, and expensive process of evaluating, planning, nurturing, funding,

redirecting, mentoring, and sometimes shutting down promising ideas. It takes

creativity, persistence, patience (but also impatience), and a deep understanding of

the business creation process.”

-JOHN MCDONNELLChairman, BioSTL

BioGenerator is an evergreen investor that creates, grows, and invests in promising companies and entrepreneurs in the St. Louis region. BioGenerator identifies and de-risks commercially-promising innovations and services; advises innovators and entrepreneurs; recruits and supports entrepreneurial talent; makes staged investments grounded in rigorous due diligence; and offers access to lab space and capital equipment. We position companies to navigate the unique challenges of early-stage bioscience company development. BioGenerator’s work spans the early stage startup lifecycle of companies within the health and plant sciences, including therapeutics, diagnostics, medical devices, research tools, agriculture, and health IT.

BioGenerator is a nonprofit subsidiary of BioSTL, working together to advance the economic vitality of St. Louis by cultivating a thriving bioscience sector. BioSTL organizes business, university, and philanthropic leaders around a set of deliberate strategies that capitalize on St. Louis’ strengths in medical and plant sciences. Focus areas include: building and investing in startups through its venture development arm, BioGenerator; improving access to investment capital; ensuring appropriate physical infrastructure; promoting science- and innovation-friendly public policy; fostering a more inclusive entrepreneurial talent pool in the region; attracting the U.S. presence of international companies; and raising global awareness of St. Louis’ strengths. BioGenerator and BioSTL staffs collaborate in the development and implementation of many of these programs.

75 52

2015 BY THE NUMBERS

30 175“BioGenerator’s model has

helped grow companies like Benson Hill into

quality, highly-attractive investments for venture

investors.”

-Scott Horner, Ph.D.Managing Director, Middleland Capital

“The St. Louis startup community is flourishing. We’ve

discovered and invested in several of our most promising companies there. I continue

to be impressed by the BioGenerator model and the

quality of their portfolio.”

- Dan Watkins, Ph.D.Managing Director, Mercury Fund

32

305 26 400 $145M

20

Board positions Investment firms engaged Investment transactions closed

Investment opportunities evaluated

Companies financed Meetings with entrepreneurs

Additional capital leveraged

Commercial grant applicants trained

Pre-investment projects funded

Lab client companies

20 South Sarah Street St. Louis, MO 63108www.biogenerator.org